Phase 1 Pancreatic Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed (through tissue or cell testing) with an advanced, inoperable, and/or spreading or returning solid tumour cancer.
• People who have a good general health and activity level, able to carry out everyday activities with little or no limitation (ECOG performance status 0 or 1).
• People who have at least one measurable tumour lesion that has not previously been treated with radiation.
• People whose tumour has a confirmed KRAS gene mutation (any type), with specific rules depending on cancer type — for example, people with non-small cell lung cancer (NSCLC) who previously had a specific mutation type called G12C already treated may not qualify under NSCLC rules; people with NSCLC who have certain other gene changes (such as EGFR, ALK, or ROS1) must have already tried targeted treatments for those changes (confirm with trial site).
• People in the earlier parts of the trial (Parts 1 and 2a) whose cancer has continued to grow or spread despite standard treatments, and for whom no further effective standard treatments are available — with specific prior treatment history requirements depending on cancer type (pancreatic, lung, bowel, or other).
• People in the later part of the trial (Part 2b) who meet specific prior treatment history requirements based on their cancer type and the treatment group (cohort) they would be assigned to — for example, some groups require no prior chemotherapy for metastatic disease, while others require one or two prior treatment regimens (confirm with trial site for the specific cohort requirements).

Who may not be able to join:

• People who currently have, or have a history of, lung inflammation (pneumonitis), interstitial lung disease (ILD), or lung scarring (pulmonary fibrosis) that required treatment with steroid medicines taken throughout the body.
• People who have a weakened immune system, or an active autoimmune disease that has required ongoing immune-suppressing medicines (such as prednisone at doses above 10 mg per day, or similar) within the past 2 years.
• People who have moderate or severe nerve damage causing sensory symptoms such as numbness or tingling (Grade 2 or higher peripheral neuropathy).
• People who have an active or significant history of serious digestive tract conditions — such as inflammatory bowel disease, ulcerative colitis, Crohn's disease, peptic ulcers, gastrointestinal bleeding, or ongoing chronic diarrhoea — that are unresolved or could increase health risks during the trial.
• People who have an active bleeding disorder, including any gastrointestinal bleeding, or who have vomited blood, had significant coughing up of blood, or had dark/tarry stools within the past 6 months.
• People who have had major surgery or completed radiation therapy within 4 weeks before joining the trial, or who received radiation therapy that covered more than 30% of the bone marrow.
• People who are known to be allergic to, or medically unable to take, any of the study drugs or medications used in the trial (a long list of specific medicines is involved — confirm with trial site).
• People who have abnormal blood cell counts or other blood-related concerns.
• People who have reduced kidney function.
• People who have abnormal liver function.

Important: Always verify eligibility with the trial site directly before applying.